Finoriq research workspace
BioCardia, Inc. (BCDA) SEC Filings & Filing Highlights
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular. Review BCDA SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
- Company
- BioCardia, Inc. (BCDA)
- Ticker
- BCDA
- Market Cap
- $9.8M
- Latest Price
- $0.8643
- Industry
- Biotech & Pharma
BioCardia, Inc. (BCDA) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for BioCardia, Inc. (BCDA).
| Event | Form | Date |
|---|---|---|
| On June 18, 2026, BioCardia, Inc. issued a press release containing its letter to shareholders,...On June 18, 2026, BioCardia, Inc. issued a press release containing its letter to shareholders, which provides an update on the Company’s b... | 8-K7.01 | 2026-06-18 |
| BioCardia, Inc.: Exchange listing issueAs previously disclosed on that certain Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 1... | 8-K3.01 | 2026-06-12 |
| BioCardia, Inc.: Corporate updateOn June 8, 2026, BioCardia, Inc. (the “Company”) issued a press release announcing that the Company sold 3,509,604 shares at an average pri... | 8-K8.01 | 2026-06-08 |
| On June 5, 2026, BioCardia, Inc. issued a press release announcing receipt of FDA minutes from...On June 5, 2026, BioCardia, Inc. issued a press release announcing receipt of FDA minutes from its Q-Sub Meeting with FDA Center for Biolog... | 8-K7.01 | 2026-06-05 |
| On May 28, 2026, BioCardia, Inc. issued a press release reporting the Consultation Record from...On May 28, 2026, BioCardia, Inc. issued a press release reporting the Consultation Record from Japan’s Pharmaceutical and Medical Device Ag... | 8-K7.01 | 2026-05-28 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.